Physician

Andrew D Laman, M.D.

According to 2025 Medicare claims, Andrew Laman, M.D. (NPI: 1467423392) practices medical oncology in the Pittsburgh, PA market, with the plurality of this provider's patient population coming from Allegheny, PA. This provider's primary affiliated billing organization is HEMATOLOGY ONCOLOGY ASSOCIATION (NPI: 1114994324; TIN: 251762980) and primary practice location at 15122-2432.

Laman's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 208 traditional Medicare patients, billed 643 HCPCS/CPT codes, and received $43,259 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 1,862 prescription claims across 325 beneficiaries totaling $7,442,057 in drug costs, led by Ibrance (Palbociclib). 2023 DME data shows 17 claims. Open Payments data shows 1 records totaling $10,000. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,449,891 to $7,442,057. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	238	639	$37,383
2016	299	726	$40,773
2017	327	697	$35,741
2018	270	652	$36,217
2019	285	732	$43,416
2020	287	674	$44,065
2021	208	576	$44,835
2022	208	518	$40,834
2023	222	489	$37,825
2024	208	643	$43,259

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	200	1,144	$1,449,891
2016	237	1,352	$2,184,024
2017	243	1,404	$2,617,853
2018	247	1,540	$4,137,009
2019	253	1,693	$4,180,914
2020	273	1,685	$4,965,547
2021	294	1,904	$5,621,896
2022	260	1,720	$4,312,969
2023	273	1,624	$4,633,780
2024	325	1,862	$7,442,057

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	79	$23,116
2016	N/R	42	$1,366
2017	N/R	79	$3,903
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	13	$1,640
2022	N/R	N/R	N/R
2023	N/R	17	$4,896
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	72	231	$102
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	29	29	$95
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	73	106	$64
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	46	51	$39
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	94	168	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ibrance	Palbociclib	61	1,708	$971,882
Imbruvica	Ibrutinib	49	1,460	$856,767
Calquence	Acalabrutinib Maleate	45	1,350	$686,809
Revlimid	Lenalidomide	36	998	$637,062
Pomalyst	Pomalidomide	23	644	$527,985

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	0	$0	N/R
Research Payments	Reported research-related payment or transfer-of-value amount.	1	$10,000	PFIZER INC.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Andrew D. Laman, M.D.?

Tedicare shows public-source Medicare data for Andrew D. Laman, M.D. (NPI 1467423392), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Andrew D. Laman, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Andrew D. Laman, M.D.?

Andrew D. Laman, M.D. is linked to HEMATOLOGY ONCOLOGY ASSOCIATION (billing NPI 1114994324) in the available physician profile data.

Does Andrew D. Laman, M.D. have Open Payments data?

Andrew D. Laman, M.D. has 1 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.